| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A critical review of the Royal Society's report on personalized medicine
|
Jain, Kewal K.
|
|
2006
|
|
13-14 |
p. 573-575
3 p.
|
artikel
|
| 2 |
A generic operational strategy to qualify translational safety biomarkers
|
Matheis, Katja
|
|
2011
|
|
13-14 |
p. 600-608
9 p.
|
artikel
|
| 3 |
Alpha4-integrin antagonism — an effective approach for the treatment of inflammatory diseases?
|
Davenport, Richard J.
|
|
2007
|
|
13-14 |
p. 569-576
8 p.
|
artikel
|
| 4 |
A molecular informatics view on best practice in multi-parameter compound optimization
|
Lusher, Scott J.
|
|
2011
|
|
13-14 |
p. 555-568
14 p.
|
artikel
|
| 5 |
An overview of natural polymers for oral insulin delivery
|
Sonia, T.A.
|
|
2012
|
|
13-14 |
p. 784-792
9 p.
|
artikel
|
| 6 |
Application of technologies and parallel chemistry for the generation of actives against biological targets
|
Edwards, Paul
|
|
2008
|
|
13-14 |
p. 633-634
2 p.
|
artikel
|
| 7 |
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements
|
Schwarz, Adam J.
|
|
2011
|
|
13-14 |
p. 583-593
11 p.
|
artikel
|
| 8 |
Benzothiazole derivatives as antitumour agents
|
Edwards, Paul
|
|
2006
|
|
13-14 |
p. 671-672
2 p.
|
artikel
|
| 9 |
Beyond data integration
|
Slater, Ted
|
|
2008
|
|
13-14 |
p. 584-589
6 p.
|
artikel
|
| 10 |
Big nation, nano dream – the prospects of India's nanotech revolution
|
Agoramoorthy, Govindasamy
|
|
2010
|
|
13-14 |
p. 495-498
4 p.
|
artikel
|
| 11 |
Biodiversity of small molecules – a new perspective in screening set selection
|
Petrone, Paula M.
|
|
2013
|
|
13-14 |
p. 674-680
7 p.
|
artikel
|
| 12 |
Biosynthesis, degradation and pharmacological importance of the fatty acid amides
|
Farrell, Emma K.
|
|
2008
|
|
13-14 |
p. 558-568
11 p.
|
artikel
|
| 13 |
Calcium phosphate biomaterials as bone drug delivery systems: a review
|
Verron, Elise
|
|
2010
|
|
13-14 |
p. 547-552
6 p.
|
artikel
|
| 14 |
Can emerging drug classes improve R&D productivity?
|
Meier, Christoph
|
|
2013
|
|
13-14 |
p. 607-609
3 p.
|
artikel
|
| 15 |
Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004–2009
|
Zhang, Litao
|
|
2012
|
|
13-14 |
p. 733-740
8 p.
|
artikel
|
| 16 |
Cell microarrays in drug discovery
|
Castel, David
|
|
2006
|
|
13-14 |
p. 616-622
7 p.
|
artikel
|
| 17 |
Challenges and opportunities for oncology biomarker discovery
|
Deyati, Avisek
|
|
2013
|
|
13-14 |
p. 614-624
11 p.
|
artikel
|
| 18 |
Chemical microarray: a new tool for drug screening and discovery
|
Ma, Haiching
|
|
2006
|
|
13-14 |
p. 661-668
8 p.
|
artikel
|
| 19 |
China commits itself to biotech in healthcare
|
Kermani, Faiz
|
|
2007
|
|
13-14 |
p. 501-503
3 p.
|
artikel
|
| 20 |
Chromatin modifying agents – the cutting edge of anticancer therapy
|
Kwa, Faith A.A.
|
|
2011
|
|
13-14 |
p. 543-547
5 p.
|
artikel
|
| 21 |
Clinical value of circulating endothelial cell detection in oncology
|
Kraan, Jaco
|
|
2012
|
|
13-14 |
p. 710-717
8 p.
|
artikel
|
| 22 |
Collaborative virtual organisation and infrastructure for drug discovery
|
Hardy, Barry
|
|
2013
|
|
13-14 |
p. 681-686
6 p.
|
artikel
|
| 23 |
Compound promiscuity: what can we learn from current data?
|
Hu, Ye
|
|
2013
|
|
13-14 |
p. 644-650
7 p.
|
artikel
|
| 24 |
Considering the impact drug-like properties have on the chance of success
|
Yusof, Iskander
|
|
2013
|
|
13-14 |
p. 659-666
8 p.
|
artikel
|
| 25 |
Contents
|
|
|
2010
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 26 |
Contents
|
|
|
2010
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 27 |
Contents
|
|
|
2008
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 28 |
Contents
|
|
|
2007
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 29 |
Contents
|
|
|
2008
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 30 |
Contents
|
|
|
2013
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 31 |
Contents
|
|
|
2013
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 32 |
Contents
|
|
|
2011
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 33 |
Contents
|
|
|
2011
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 34 |
Contents
|
|
|
2012
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 35 |
Contents
|
|
|
2012
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 36 |
Contents page 2
|
|
|
2009
|
|
13-14 |
p. iii-
1 p.
|
artikel
|
| 37 |
Contents page 1
|
|
|
2009
|
|
13-14 |
p. i-
1 p.
|
artikel
|
| 38 |
Creating more effective antidepressants: clues from the clinic
|
Rasmussen, Kurt
|
|
2006
|
|
13-14 |
p. 623-631
9 p.
|
artikel
|
| 39 |
Cryopreserved cells facilitate cell-based drug discovery
|
Zaman, Guido J.R.
|
|
2007
|
|
13-14 |
p. 521-526
6 p.
|
artikel
|
| 40 |
Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
|
Broussalis, Erasmia
|
|
2012
|
|
13-14 |
p. 671-684
14 p.
|
artikel
|
| 41 |
Current trends in antimicrobial agent research: chemo- and bioinformatics approaches
|
Hammami, Riadh
|
|
2010
|
|
13-14 |
p. 540-546
7 p.
|
artikel
|
| 42 |
Designing better drugs: predicting cytochrome P450 metabolism
|
de Groot, Marcel J.
|
|
2006
|
|
13-14 |
p. 601-606
6 p.
|
artikel
|
| 43 |
Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms
|
Tang, Bo
|
|
2008
|
|
13-14 |
p. 606-612
7 p.
|
artikel
|
| 44 |
Developments in fluorescent probes for receptor research
|
Leopoldo, Marcello
|
|
2009
|
|
13-14 |
p. 706-712
7 p.
|
artikel
|
| 45 |
Diary
|
|
|
2006
|
|
13-14 |
p. 673-
1 p.
|
artikel
|
| 46 |
Dimerization of chemokine receptors in living cells: key to receptor function and novel targets for therapy
|
Wang, Jinhai
|
|
2008
|
|
13-14 |
p. 625-632
8 p.
|
artikel
|
| 47 |
Downscaling functional bioassays by single-molecule techniques
|
Hong, Feng
|
|
2006
|
|
13-14 |
p. 640-645
6 p.
|
artikel
|
| 48 |
Driving operational excellence across research
|
Cunningham, Mark R.
|
|
2011
|
|
13-14 |
p. 541-542
2 p.
|
artikel
|
| 49 |
Editorial Board
|
|
|
2007
|
|
13-14 |
p. v-
1 p.
|
artikel
|
| 50 |
Electronic health records: Implications for drug discovery
|
Yao, Lixia
|
|
2011
|
|
13-14 |
p. 594-599
6 p.
|
artikel
|
| 51 |
Emerging DNA sequencing technologies for human genomic medicine
|
Strausberg, Robert L.
|
|
2008
|
|
13-14 |
p. 569-577
9 p.
|
artikel
|
| 52 |
Expanding the medicinally relevant chemical space with compound libraries
|
López-Vallejo, Fabian
|
|
2012
|
|
13-14 |
p. 718-726
9 p.
|
artikel
|
| 53 |
From fragment to clinical candidate—a historical perspective
|
Chessari, Gianni
|
|
2009
|
|
13-14 |
p. 668-675
8 p.
|
artikel
|
| 54 |
Gastrointestinal weight-loss surgery: glimpses at the molecular level
|
Freudenberg, Johannes M.
|
|
2013
|
|
13-14 |
p. 625-636
12 p.
|
artikel
|
| 55 |
Grid computing in large pharmaceutical molecular modeling
|
Claus, Brian L.
|
|
2008
|
|
13-14 |
p. 578-583
6 p.
|
artikel
|
| 56 |
Hakan Bjorklund, CEO of Nycomed, talks growth
|
|
|
2010
|
|
13-14 |
p. 499-501
3 p.
|
artikel
|
| 57 |
Homology modeling in drug discovery: current trends and applications
|
Cavasotto, Claudio N.
|
|
2009
|
|
13-14 |
p. 676-683
8 p.
|
artikel
|
| 58 |
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals
|
van Roey, Jens
|
|
2008
|
|
13-14 |
p. 601-605
5 p.
|
artikel
|
| 59 |
Immunoinformatics: Current trends and future directions
|
Tong, Joo Chuan
|
|
2009
|
|
13-14 |
p. 684-689
6 p.
|
artikel
|
| 60 |
Impact of 5-HT3 receptor antagonists on peripheral and central diseases
|
Fakhfouri, Gohar
|
|
2012
|
|
13-14 |
p. 741-747
7 p.
|
artikel
|
| 61 |
Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target
|
Wamil, Malgorzata
|
|
2007
|
|
13-14 |
p. 504-520
17 p.
|
artikel
|
| 62 |
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
|
Reddy, V. Prakash
|
|
2006
|
|
13-14 |
p. 646-654
9 p.
|
artikel
|
| 63 |
Interactive design of generic chemical patterns
|
Schomburg, Karen T.
|
|
2013
|
|
13-14 |
p. 651-658
8 p.
|
artikel
|
| 64 |
Interference with islet-specific homing of autoreactive T cells: an emerging therapeutic strategy for type 1 diabetes
|
Savinov, Alexei Y.
|
|
2010
|
|
13-14 |
p. 531-539
9 p.
|
artikel
|
| 65 |
Into the valley of death: research to innovation
|
Hudson, John
|
|
2013
|
|
13-14 |
p. 610-613
4 p.
|
artikel
|
| 66 |
July Diary
|
|
|
2007
|
|
13-14 |
p. 589-
1 p.
|
artikel
|
| 67 |
Local delivery of proteins and the use of self-assembling peptides
|
Segers, Vincent F.M.
|
|
2007
|
|
13-14 |
p. 561-568
8 p.
|
artikel
|
| 68 |
Managing freedom: Managing researchers as if they were warriors
|
Uitdehaag, Joost
|
|
2008
|
|
13-14 |
p. 555-557
3 p.
|
artikel
|
| 69 |
2-Methoxyestradiol – a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents
|
Sutherland, Tara E.
|
|
2007
|
|
13-14 |
p. 577-584
8 p.
|
artikel
|
| 70 |
Mining the GEMS – a novel platform technology targeting post-transcriptional control mechanisms
|
Bhattacharyya, Anuradha
|
|
2007
|
|
13-14 |
p. 553-560
8 p.
|
artikel
|
| 71 |
Molecular determinants of drug–receptor binding kinetics
|
Pan, Albert C.
|
|
2013
|
|
13-14 |
p. 667-673
7 p.
|
artikel
|
| 72 |
Myostatin: more than just a regulator of muscle mass
|
Argilés, Josep M.
|
|
2012
|
|
13-14 |
p. 702-709
8 p.
|
artikel
|
| 73 |
Navigating structure–activity landscapes
|
Bajorath, Jürgen
|
|
2009
|
|
13-14 |
p. 698-705
8 p.
|
artikel
|
| 74 |
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
|
Krystal, John H.
|
|
2009
|
|
13-14 |
p. 690-697
8 p.
|
artikel
|
| 75 |
New frontiers in ethnomedicine: exploring the Angolan indigenous pharmacopeia for novel antimalarial drugs
|
Rangel Campos, Walter
|
|
2012
|
|
13-14 |
p. 651-653
3 p.
|
artikel
|
| 76 |
New pharmacological approaches to atrial fibrillation
|
Milnes, James T.
|
|
2012
|
|
13-14 |
p. 654-659
6 p.
|
artikel
|
| 77 |
New working paradigms in research laboratories
|
Keighley, Wilma
|
|
2009
|
|
13-14 |
p. 625-629
5 p.
|
artikel
|
| 78 |
Orphan drug development: an economically viable strategy for biopharma R&D
|
Meekings, Kiran N.
|
|
2012
|
|
13-14 |
p. 660-664
5 p.
|
artikel
|
| 79 |
Overcoming psychological barriers to good discovery decisions
|
Chadwick, Andrew T.
|
|
2010
|
|
13-14 |
p. 561-569
9 p.
|
artikel
|
| 80 |
Pandemic and seasonal influenza: therapeutic challenges
|
Memoli, Matthew J.
|
|
2008
|
|
13-14 |
p. 590-595
6 p.
|
artikel
|
| 81 |
Parallel chemistry libraries for the discovery of biologically active substances
|
Edwards, Paul John
|
|
2010
|
|
13-14 |
p. 579-580
2 p.
|
artikel
|
| 82 |
Particulate vaccines: on the quest for optimal delivery and immune response
|
De Temmerman, Marie-Luce
|
|
2011
|
|
13-14 |
p. 569-582
14 p.
|
artikel
|
| 83 |
Pathological changes in tight junctions and potential applications into therapies
|
Takahashi, Azusa
|
|
2012
|
|
13-14 |
p. 727-732
6 p.
|
artikel
|
| 84 |
Peptoid positional scanning libraries for identification of multidrug resistance reversal agents
|
Edwards, Paul
|
|
2006
|
|
13-14 |
p. 669-670
2 p.
|
artikel
|
| 85 |
Picking up the pieces with FBDD or FADD: invest early for future success
|
Whittaker, Mark
|
|
2009
|
|
13-14 |
p. 623-624
2 p.
|
artikel
|
| 86 |
PLK1 as an oncology target: current status and future potential
|
McInnes, Campbell
|
|
2011
|
|
13-14 |
p. 619-625
7 p.
|
artikel
|
| 87 |
Portfolio management in early stage drug discovery – a traveler's guide through uncharted territory
|
Betz, Ulrich A.K.
|
|
2011
|
|
13-14 |
p. 609-618
10 p.
|
artikel
|
| 88 |
Preclinical and clinical safety of monoclonal antibodies
|
Tabrizi, Mohammad A.
|
|
2007
|
|
13-14 |
p. 540-547
8 p.
|
artikel
|
| 89 |
Present perspectives on flaviviral chemotherapy
|
Ghosh, Debapriya
|
|
2008
|
|
13-14 |
p. 619-624
6 p.
|
artikel
|
| 90 |
Proteoglycans on bone tumor development
|
Velasco, Carmen Ruiz
|
|
2010
|
|
13-14 |
p. 553-560
8 p.
|
artikel
|
| 91 |
Proteomics: addressing the challenges of osteoarthritis
|
De Ceuninck, Frédéric
|
|
2009
|
|
13-14 |
p. 661-667
7 p.
|
artikel
|
| 92 |
Proton pump inhibitors: actions and reactions
|
Mullin, James M.
|
|
2009
|
|
13-14 |
p. 647-660
14 p.
|
artikel
|
| 93 |
P2Y nucleotide receptors: promise of therapeutic applications
|
Jacobson, Kenneth A.
|
|
2010
|
|
13-14 |
p. 570-578
9 p.
|
artikel
|
| 94 |
Recent developments in screening natural product combinatorial libraries
|
Edwards, Paul
|
|
2007
|
|
13-14 |
p. 585-586
2 p.
|
artikel
|
| 95 |
Recent developments in the production of ligands directed against the group III metabotropic glutamate and the VLA-4 receptors
|
Edwards, Paul
|
|
2007
|
|
13-14 |
p. 587-588
2 p.
|
artikel
|
| 96 |
Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
|
Haurum, John S.
|
|
2006
|
|
13-14 |
p. 655-660
6 p.
|
artikel
|
| 97 |
Relevance of systems pharmacology in drug discovery
|
Cucurull-Sanchez, Lourdes
|
|
2012
|
|
13-14 |
p. 665-670
6 p.
|
artikel
|
| 98 |
Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering
|
Schamberger, Jens
|
|
2011
|
|
13-14 |
p. 636-641
6 p.
|
artikel
|
| 99 |
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy
|
Bayry, Jagadeesh
|
|
2007
|
|
13-14 |
p. 548-552
5 p.
|
artikel
|
| 100 |
Ribosome-inactivating proteins: current status and biomedical applications
|
Puri, Munish
|
|
2012
|
|
13-14 |
p. 774-783
10 p.
|
artikel
|
| 101 |
Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
|
Robinson, Martyn K.
|
|
2013
|
|
13-14 |
p. 637-643
7 p.
|
artikel
|
| 102 |
Screening for positive allosteric modulators of biological targets
|
Groebe, Duncan R.
|
|
2006
|
|
13-14 |
p. 632-639
8 p.
|
artikel
|
| 103 |
Screening in a spirit haunted world
|
Shoichet, Brian K.
|
|
2006
|
|
13-14 |
p. 607-615
9 p.
|
artikel
|
| 104 |
Sir David Weatherall reflects on genetics and personalized medicine
|
Knies-Bamforth, Ulrike
|
|
2006
|
|
13-14 |
p. 576-579
4 p.
|
artikel
|
| 105 |
Software for computational peptide identification from MS–MS data
|
Xu, Changjiang
|
|
2006
|
|
13-14 |
p. 595-600
6 p.
|
artikel
|
| 106 |
Spleen tyrosine kinases: biology, therapeutic targets and drugs
|
Riccaboni, Mauro
|
|
2010
|
|
13-14 |
p. 517-530
14 p.
|
artikel
|
| 107 |
Standards for reporting bioscience data: a forward look
|
Taylor, Chris F.
|
|
2007
|
|
13-14 |
p. 527-533
7 p.
|
artikel
|
| 108 |
Targeting endothelin receptors for pharmacotherapy of ischemic stroke: current scenario and future perspectives
|
Kaundal, Ravinder K.
|
|
2012
|
|
13-14 |
p. 793-804
12 p.
|
artikel
|
| 109 |
The art of antibody process development
|
Steinmeyer, David E.
|
|
2008
|
|
13-14 |
p. 613-618
6 p.
|
artikel
|
| 110 |
The corticotropin-releasing factor system in inflammatory bowel disease: Prospects for new therapeutic approaches
|
Paschos, Konstantinos A.
|
|
2009
|
|
13-14 |
p. 713-720
8 p.
|
artikel
|
| 111 |
The impact of epigenomics on future drug design and new therapies
|
Hamm, Christopher A.
|
|
2011
|
|
13-14 |
p. 626-635
10 p.
|
artikel
|
| 112 |
Therapeutic modulation of k-ras signaling in colorectal cancer
|
Krens, Lisanne L.
|
|
2010
|
|
13-14 |
p. 502-516
15 p.
|
artikel
|
| 113 |
Therapeutic stratagems for vascular degenerative disorders of the posterior eye
|
Jain, Gaurav K.
|
|
2012
|
|
13-14 |
p. 748-759
12 p.
|
artikel
|
| 114 |
To measure is to know: an approach to CADD performance metrics
|
Loughney, Deborah
|
|
2011
|
|
13-14 |
p. 548-554
7 p.
|
artikel
|
| 115 |
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation
|
Williams, Antony J.
|
|
2012
|
|
13-14 |
p. 685-701
17 p.
|
artikel
|
| 116 |
Transforming fragments into candidates: small becomes big in medicinal chemistry
|
de Kloe, Gerdien E.
|
|
2009
|
|
13-14 |
p. 630-646
17 p.
|
artikel
|
| 117 |
Tuberculosis: from molecular pathogenesis to effective drug carrier design
|
Dube, Devyani
|
|
2012
|
|
13-14 |
p. 760-773
14 p.
|
artikel
|
| 118 |
Vaccines against intracellular bacterial pathogens
|
Titball, Richard W.
|
|
2008
|
|
13-14 |
p. 596-600
5 p.
|
artikel
|
| 119 |
Virtual ligand screening: strategies, perspectives and limitations
|
Klebe, Gerhard
|
|
2006
|
|
13-14 |
p. 580-594
15 p.
|
artikel
|
| 120 |
Water, water everywhere — except where it matters?
|
Homans, Steve W.
|
|
2007
|
|
13-14 |
p. 534-539
6 p.
|
artikel
|
Tijdschrift beschrijving